IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
Status:
Recruiting
Trial end date:
2022-06-15
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the side effects and best dose of IRX-2 when given together with
cyclophosphamide and nivolumab in treating patients with liver cancer that has come back or
spread to other parts of the body and does not response to treatment. Biological therapies,
such as IRX-2, may stimulate or suppress the immune system in different ways and stop tumor
cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such
as nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Giving IRX-2, cyclophosphamide, and nivolumab may
work better than the IRX?2 regimen alone in treating patients with hepatocellular carcinoma.